mifamurtide

mifamurtide

A fully synthetic lipophilic derivative of muramyl dipeptide, which is an immune stimulatory component of cell walls from Mycobacterium, used to manage high-grade, non-metastasising, resectable osteosarcoma after surgical excision in children to young adults (age 2 to 30).
 
Adverse effects
Fever (90%), tachycardia (50%), constipation (10%), vomiting, fatigue, infections, anaemia, anorexia, headache, diarrhoea.

Prognosis
Mifamurtide-treated patients have a 30% lower mortality than those treated with chemotherapy.
References in periodicals archive ?
Immunotherapies targeting this axis have shown great antitumor potential and, for the case of Mifamurtide, come the closest to regular clinical use in osteosarcoma [40].
White, "Effectiveness of mifamurtide in addition to standard chemotherapy for high-grade osteosarcoma: a systematic review," JBI Database of Systematic Reviews and Implementation Reports, vol.
26 October 2011 - The UK National Institute for Health and Clinical Excellence (NICE) said today it had issued final guidance recommending the use of Japanese Takeda's (TYO:4502) Mepact (mifamurtide) in combination with postoperative multi-agent chemotherapy as an option for treating high-grade resectable non-metastatic osteosarcoma in children and young people.
Interferon alpha and Mifamurtide (liposomal muramyl tripeptide phosphatidyl ethanolamine; Mepact[R]) have been tried as adjuvants in treatment of osteosarcoma with encouraging results of improved DFS disease-free survival (DFS) of 7%.
Three of the drugs were approved by the EMA but not by the FDA: Ceplene (histamine dihydrochloride), Mepact (mifamurtide), and Yondelis (trabectedin).
The analysis of Mifamurtide was not only challenging, owing to the physical and chemical properties of the molecular entities themselves, but were compounded by the need for a transition from older methods to new ones that met current standards ...
Food and Drug Administration (FDA) for Junovan (mifamurtide for injection), requesting approval for its use in the treatment of newly diagnosed resectable high grade osteosarcoma patients following surgical resection in combination with multiple agent chemotherapy.
Bielack, "Review of mifamurtide in the treatment of patients with osteosarcoma," Therapeutics and Clinical Risk Management, vol.
8 September 2011 - The National Institute for Health and Clinical Excellence (NICE) said yesterday it has published final draft guidance recommending the use of Japanese Takeda Pharmaceutical Company Limited's (TYO:4502) Mepact (mifamurtide).
8 October 2010 - In draft guidance published on Friday, the National Institute for Health and Clinical Excellence (NICE) said that Takeda Pharmaceutical Company Limited's (TYO: 4502) Mepact (mifamurtide), is not recommended for NHS use in combination with post-operative chemotherapy drugs for the treatment of high-grade non-metastatic, surgically treatable osteosarcoma.
8 February 2010 - Japanese Takeda Pharmaceutical Company Limited (TYO: 4502) and its wholly-owned subsidiary, Takeda Pharmaceuticals Europe Limited, said last Monday that Mepact (mifamurtide), a treatment to improve survival in patients with osteosarcoma (malignant bone cancer), is now commercially available in the European Union (EU).